Medtronic Announces Groundbreaking Results from ADAPT-PD Trial, Showcasing Effectiveness of BrainSense™ Adaptive DBS for Parkinson's Patients
I'm PortAI, I can summarize articles.
Medtronic plc has published results from the ADAPT-PD trial in JAMA Neurology, showcasing the effectiveness of its BrainSense™ Adaptive deep brain stimulation (aDBS) for Parkinson’s disease. This pivotal trial, the largest of its kind, involved leading neurologists and neurosurgeons across 10 centers in the U.S., Canada, and Europe, marking a significant advancement in managing Parkinson’s disease through closed-loop neuromodulation technology.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments